Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.49 |
| ▸ | F13A1 | P00488 | 11/20 | 0.49 |
| ▸ | TGM1 | P22735 | 8/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042200 | 0.79 | TDP1 (0.65) | TGM2F13A1TGM1EPHX2TGM3 | |
| SCHEMBL113805 | 0.78 | GPR119 (0.55) | GPR119POLBMEN1KMT2A | |
| SCHEMBL18410584 | 0.77 | TGM2 (0.65) | TGM2F13A1TGM1POLBMEN1 | |
| SCHEMBL10042199 | 0.77 | EPHX2 (0.53) | TGM2F13A1TGM1EPHX2TGM3 | |
| SCHEMBL16990306 | 0.77 | TGM2 (0.52) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL1955697 | 0.76 | ALDH1A1 (0.62) | TGM2F13A1TGM1POLBMEN1 | |
| SCHEMBL1180685 | 0.76 | TGM2 (0.50) | TGM2F13A1TGM1POLB | |
| SCHEMBL4447626 | 0.75 | TGM2 (0.49) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL31399725 | 0.74 | TSHR (0.50) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL14837774 | 0.74 | TGM2 (0.48) | TGM2F13A1TGM1TGM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | TGM2 335/4885F13A1 3726/4885TGM1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.